disease modifying therapies
play

Disease Modifying Therapies David Paling - Sheffield Rachel - PowerPoint PPT Presentation

Jan 30, 2024 •386 likes •907 views

Disease Modifying Therapies David Paling - Sheffield Rachel Dorsey-Campbell - Imperial Timeline of treatments Timeline of treatments Lemtrada Cladribine Plegridy Tecfidera Ocrelizumab Aubagio Daclizumab Plegridy Betaferon Avonex

  1. Disease Modifying Therapies David Paling - Sheffield Rachel Dorsey-Campbell - Imperial

  2. Timeline of treatments Timeline of treatments Lemtrada Cladribine Plegridy Tecfidera Ocrelizumab Aubagio Daclizumab Plegridy Betaferon Avonex Copaxone Mitoxantrone Tysabri Fingolimod 1994 2017 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 2016

  3. Decision on treatments • Mechanism of action • Mode of administration • Monitoring and drug frequency • Pregnancy and breast feeding • Side effects • PML • Efficacy • Sequencing vs Escalation

  4. Decision on treatments • Mechanism of action • Mode of administration • Monitoring and drug frequency • Pregnancy and breast feeding • Side effects • PML • Efficacy • Sequencing vs Escalation

  5. Pathology Pathology of relapsing MS

  6. Treatments 1. Immunomodulation 2. Reduced cell proliferation IFN Beta/ GA Teriflunomide DMF 3. Targeted cell lysis Alemtuzumab Cladribine 4. Anti Migratory Ocrelizumab Fingolimod AHSCT Natalizumab

  7. Mechanisms of action Cell lysis Immuno Modulatory AHSCT Dimethyl fumarate IFNs Glatiramer acetate CD20 Alemtuzumab Modulation of Activation of nrf 2 Activation of CD52 Lysis of mature Th1:Th2 balance IFN-response genes responsive genes B and T cells Cladribine Ocrelizumab BBB Anti-migratory Reduced proliferation Lymph Limits pyrimidine Teriflunomide node availability for Fingolimod Natalizumab rapid cell division S1P1 α 4 - T integrin B Periphery CNS B, B cell; BBB, blood–brain barrier; CNS, central nervous system; IFN, interferon; IL2, interleukin 2; nrf 2, nuclear factor)-like 2; S1P1, sphingosine-1-phosphate receptor 1; T, T cell; Th, T-helper cell Adapted from: 1. Loleit V et al. Curr Pharm Biotechnol. 2014;15:276–96; 2. Scannevin R et al . J Pharmacol Exp Ther. 2012;341:274–84; 3. Chen H et al. J Clin Invest. 2014;124:2188–92. Heckler et al. Mol Neurobiol. 2013;48:737-56

  8. Decision on treatments • Mechanism of action • Mode of administration • Monitoring and drug frequency • Pregnancy and breast feeding • Side effects • PML • Efficacy • Sequencing vs Escalation

  9. Mode of administration

  10. Decision on treatments • Mechanism of action • Mode of administration • Monitoring and drug frequency • Pregnancy and breast feeding • Side effects • PML • Efficacy • Sequencing vs Escalation

  11. Start Betainterferon May 1 2006 2007 Apr Jun Aug Oct Dec Feb Apr Apr 1 Nov 2 May 1 Screening Blood Tests Blood Test Blood Test Start Teriflunamide Blood Pressure Blood Pressure Blood Pressure Blood Pressure May 1 Aug 1 Nov 1 Feb 1 May 1 2016 2017 Apr Jun Aug Oct Dec Feb Apr Apr 1 Screening Blood Tests 14 Blood Tests in one year Graves Disease Renal Failure Hepatic Failure TTP

  12. Monitoring Blood tests • None – GA • At the time of infusions – 1 monthly Natalizumab (although other MRI monitoring) – 6 monthly Ocrelizumab • 3-6 months – DMF, Beta interferons, Cladribine • 1 monthly – Alemtuzumab • Every 2 weeks for 6 months – Teriflunamide

  14. Monitoring

  15. MS DMT monitoring burden

  16. Admin Support

  17. Decision on treatments • Mechanism of action • Mode of administration • Monitoring and drug frequency • Pregnancy and breast feeding • Side effects • PML • Efficacy • Sequencing vs Escalation

  18. Pregnancy

  21. Decision on treatments • Mechanism of action • Mode of administration • Monitoring and drug frequency • Pregnancy and breast feeding • Side effects • PML • Efficacy • Sequencing vs Escalation

  22. Side effects

  23. Side effects

  24. Decision on treatments • Mechanism of action • Mode of administration • Monitoring and drug frequency • Pregnancy and breast feeding • Side effects • PML • Efficacy • Sequencing vs Escalation

  25. PML

  26. PML Mortality 30 25 20 9 fold 15 10 5 0 Symptoms Asymptomatic Mortality

  27. PML

  28. PML

  30. Decision on treatments • Mechanism of action • Mode of administration • Monitoring and drug frequency • Pregnancy and breast feeding • Side effects • PML • Efficacy • Sequencing vs Escalation

  31. Efficacy

  32. Treatments for MS AHSCT Alemtuzumab Natalizumab Cladribine Ocrelizumab Fingolimod Fumarate (BG-12) BIFN Teriflunomide GA Treatment burden

  33. Less effective Less More effective Risk vs Benefit dangerous Restricted indication 2 relapses in 2 years All active MS Copaxone Alemtuzumab Fingolimod Interferon Beta Natalizumab Ocrelizumab Cladribine Dimethyl Fumarate AHSCT Teriflunamide Natalizumab JCV+ Mitoxantrone More dangerous

  34. Decision on treatments • Mechanism of action • Mode of administration • Monitoring and drug frequency • Pregnancy and breast feeding • Side effects • PML • Efficacy • Sequencing vs Escalation

  35. Induction vs escalation

  36. Making treatment decision Risk and burden of treatment Risk of MS Age Plans for pregnancy Method of Administration Severity of relapses Frequency of administration Associated neurological disability Occupation MRI disease activity Other medical conditions Oligoclonal Bands Poor mobility (ulcers / chest infections)

  37. Evidence Base Number of papers in PubMed per year for multiple sclerosis with drug name in the title 140 120 100 80 60 40 20 0 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Glatiramer Acetate and Beta Interferon Natalizumab Fingolimod Di Methly Fumarate Alemtuzumab Cladribine

  38. Evidence Base Number of papers in PubMed per year for multiple sclerosis with Beta Interferon, Glatiramer, Natalizumab, Fingolimod, Fumarate, or Cladribine in the title 350 300 250 200 150 100 50 0 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Total Does not include Ocrelizumab, Siponimod, Posenimod, Ofatunumab

  39. 2016/17 Spend on DMTs £249,417,164 5000 physiotherapists 150 per MS centre 15 new schools Courtesy of Prof Coles, Cambridge

  40. Oh Dear YES YES - BUT yes no NO PHEW

  42. DMT algorithm • MDT – 2 neurologists, MS nurse – Pharmacists, Radiology advice

  43. Clinical Case 1 Aug 2015 Aug 2014 Weakness left leg R ON VA 2/6 2015 2016 2014 Level at T10 Oct 15: Sensory signs EDSS 2.0 Steroids Steroids MRI normal MRI lesions

  44. Clinical case 1

  45. Clinical Case 1 • Chose DMF • No need for MDT • Blueteq form

  46. Case 2 Aug 2015 Nov 16 Aug 2014 Weakness left leg Incoordination R ON VA 2/6 2015 2016 2017 2014 2018 Level at T10 EDSS 2.0 Oct 15: Sensory signs Oct 16: EDSS 2.0 Well EDSS 0 Steroids Dimethyl Fumarate Steroids Steroids MRI normal MRI lesions MRI new lesions and contrast enhancing lesions

  47. Case 2

  48. Case 2 Aug 2014 Aug 2015 Nov 16 R ON VA 2/6 Weakness left leg Incoordination 2015 2016 2017 2014 2018 MRI normal Sexual dysfunction EDSS 2.0 Feb 17 Aug 17 Oct 15: Oct 16: Ocrelizumab EDSS 0 Sensory changes leg Well EDSS 1.5 EDSS 2.0 EDSS 0 Steroids Dimethyl Fumarate Ocrelizumab Steroids Steroids

  49. Case 2 Odds ratios of relapses over three years based upon disease activity in the first year 12 * 10 8 6 4 2 0 No relapses or new lesions Relapses without new lesions New lesions without relapses Relapses with new lesions Odds ratio of relapses in next 3 years Rio et al. Multiple Sclerosis 2009;15:848

  50. If that doesn’t work

  51. Disease Modifying Therapies David Paling - Sheffield Rachel Dorsey-Campbell - Imperial

Recommend

Novel Disease-Modifying Therapies Faculty Moderator Stephen Krieger, MD Edward Fox, MD, PhD

Novel Disease-Modifying Therapies Faculty Moderator Stephen Krieger, MD Edward Fox, MD, PhD

Shifting the Treatment Paradigm for Multiple Sclerosis: Advances in Pathophysiology and Emergence of Novel Disease-Modifying Therapies Faculty Moderator Stephen Krieger, MD Edward Fox, MD, PhD Associate Professor of Neurology Director,

549 views • 39 slides
Inhibition of Fyn Kinase for Disease- Modifying Therapy of Alzheimers Disease Stephen M.

Inhibition of Fyn Kinase for Disease- Modifying Therapy of Alzheimers Disease Stephen M.

Inhibition of Fyn Kinase for Disease- Modifying Therapy of Alzheimers Disease Stephen M. Strittmatter, M.D., Ph.D. Vince Coates Professor Neurology Director, Cellular Neuroscience, Neurodegeneration & Repair Director, Memory Disorders

784 views • 55 slides
HD journal presentation Godinho et al, Delivering a disease- modifying treatment for

HD journal presentation Godinho et al, Delivering a disease- modifying treatment for

Background for HD journal presentation Godinho et al, Delivering a disease- modifying treatment for Huntingtons disease, Drug Discovery Today , 2014 Abstract The human HTT gene and protein RNA interference (RNAi): short hairpin (SH) RNAs or

554 views • 14 slides
Disease Monitoring James W. Stark, MD, FAAN TISCH MS RESEARCH CENTER OF NEW YORK 22 ND ANNUAL

Disease Monitoring James W. Stark, MD, FAAN TISCH MS RESEARCH CENTER OF NEW YORK 22 ND ANNUAL

Disease Monitoring James W. Stark, MD, FAAN TISCH MS RESEARCH CENTER OF NEW YORK 22 ND ANNUAL PATIENT SYMPOSIUM Timeline of MS Disease Modifying Therapies 1980s 1990s 2000s 2010s Future Gilenya Ibudilast Aubagio Novantrone

410 views • 10 slides
When should disease-modifying treatments be discontinued in patients with multiple sclerosis? An

When should disease-modifying treatments be discontinued in patients with multiple sclerosis? An

When should disease-modifying treatments be discontinued in patients with multiple sclerosis? An evidence-based review with expert recommendations. Learning objective To understand the factors relevant to the decision of whether a patient

539 views • 15 slides
Parkinson s Disease: Device Aided Therapies Jawad A. Bajwa, MD National Neuroscience

Parkinson s Disease: Device Aided Therapies Jawad A. Bajwa, MD National Neuroscience

Parkinson s Disease: Device Aided Therapies Jawad A. Bajwa, MD National Neuroscience Institute King Fahad Medical City Riyadh, Saudi Arabia Objectives Why to Consider Device Aided Therapies Which Patient Profiles are Best Candidates

598 views • 38 slides
Treatment guidelines for relapsing MS and the two step approach for disease modifying

Treatment guidelines for relapsing MS and the two step approach for disease modifying

Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy Klaus Schmierer, PhD FRCP Blizard Institute, Barts and The London School of Medicine & Dentistry Barts Health NHS Trust Disclosures PI of

552 views • 36 slides
The scientific and regulatory approaches to facilitating disease-modifying drug development and

The scientific and regulatory approaches to facilitating disease-modifying drug development and

The scientific and regulatory approaches to facilitating disease-modifying drug development and registration in a global environment Thomas Blaettler On behalf of the EFPIA Working Group 24-25 November 2014 London UK 1 T I T L E O F T H

372 views • 16 slides
Prospects for a Disease Modifying Claim in Schizophrenia David H. Millis, MD, MBA, PhD Medical

Prospects for a Disease Modifying Claim in Schizophrenia David H. Millis, MD, MBA, PhD Medical

Prospects for a Disease Modifying Claim in Schizophrenia David H. Millis, MD, MBA, PhD Medical Officer Division of Psychiatry Products Center for Drug Evaluation and Research U.S. Food and Drug Administration February 21, 2019 Disclaimer

572 views • 22 slides
Prospects for a Disease Modifying Claim in Neurodevelopmental Disorders Tiffany R Farchione, MD

Prospects for a Disease Modifying Claim in Neurodevelopmental Disorders Tiffany R Farchione, MD

Prospects for a Disease Modifying Claim in Neurodevelopmental Disorders Tiffany R Farchione, MD Director (Acting) Division of Psychiatry Products Center for Drug Evaluation and Research US Food & Drug Administration February 21, 2019

469 views • 20 slides
From gene discovery to therapies for rare disease a research perspective A/Prof Carol Wicking

From gene discovery to therapies for rare disease a research perspective A/Prof Carol Wicking

From gene discovery to therapies for rare disease a research perspective A/Prof Carol Wicking Director, IMB Centre for Rare Disease Research, UQ Rare Disease Summit 2015 Melbourne 27-28 March Why rare disease? Why now? Why

262 views • 12 slides
DEVELOPING NEW DIAGNOSTICS AND THERAPIES TO TREAT TUBERCULOSIS AND INFLAMMATORY DISEASE

DEVELOPING NEW DIAGNOSTICS AND THERAPIES TO TREAT TUBERCULOSIS AND INFLAMMATORY DISEASE

DEVELOPING NEW DIAGNOSTICS AND THERAPIES TO TREAT TUBERCULOSIS AND INFLAMMATORY DISEASE Bernadette Saunders University of Technology Sydney science.uts.edu.au RESEARCH FOCUS Macrophage (White Blood Cell) Function Response to

165 views • 15 slides
Gene Therapies for Rare Diseases September 13, 2018 Rare Disease Scientific Workshop Everylife

Gene Therapies for Rare Diseases September 13, 2018 Rare Disease Scientific Workshop Everylife

Gene Therapies for Rare Diseases September 13, 2018 Rare Disease Scientific Workshop Everylife Foundation for Rare Diseases Washington, DC Wilson W. Bryan Office of Tissues and Advanced Therapies (OTAT) Center for Biologics Evaluation and

510 views • 20 slides
Disease modifying therapy choices across the region covered by Sheffield Teaching Hospitals

Disease modifying therapy choices across the region covered by Sheffield Teaching Hospitals

Disease modifying therapy choices across the region covered by Sheffield Teaching Hospitals neurology service Dr Dima Dahdaleh Consultant Neurologist Royal Hallamshire Hospital Background Neurology Service in Sheffield covers a wide area MS

554 views • 16 slides
TREATING NEURODEGENERATION BY IMPROVING MITOCHONDRIAL HEALTH 1 Mitoconix Bio Ltd Mission:

TREATING NEURODEGENERATION BY IMPROVING MITOCHONDRIAL HEALTH 1 Mitoconix Bio Ltd Mission:

TREATING NEURODEGENERATION BY IMPROVING MITOCHONDRIAL HEALTH 1 Mitoconix Bio Ltd Mission: Develop disease-modifying therapies for neurodegenerative diseases by improving mitochondrial health Lead Product: P110-TAT (MTC-1203 ) a selective peptide

743 views • 27 slides
Rationales behind novel therapies for coeliac disease Ludvig M. Sollid Director (CIR), Professor

Rationales behind novel therapies for coeliac disease Ludvig M. Sollid Director (CIR), Professor

Rationales behind novel therapies for coeliac disease Ludvig M. Sollid Director (CIR), Professor (UiO) Coeliac UK Research Conference London, March 11, 2015 CONFLICT OF INTEREST Ludvig M. Sollid Regeneron Pharma Consulting /

547 views • 27 slides
Who are we? Service offering psychological therapies (talking therapies). Part of

Who are we? Service offering psychological therapies (talking therapies). Part of

Who are we? Service offering psychological therapies (talking therapies). Part of Improving Access to Psychological Therapies (IAPT) initiative Funded by NHS, via CCG Delivered in partnership between Bromley and Lewisham Mind,

102 views • 6 slides
Emerging Therapies for Lung Fibrosis Helen Garthwaite Respiratory Registrar/ Clinical Research

Emerging Therapies for Lung Fibrosis Helen Garthwaite Respiratory Registrar/ Clinical Research

Emerging Therapies for Lung Fibrosis Helen Garthwaite Respiratory Registrar/ Clinical Research Fellow Lung Fibrosis/Interstitial Lung Disease Disease that affects the IMPORTANT tissue that supports the lungs alveoli Inflammation and/or

637 views • 25 slides
Therapies In Schools Project BRINGING THERAPIES INTO THE HEART OF SCHOOLS Why TIS

Therapies In Schools Project BRINGING THERAPIES INTO THE HEART OF SCHOOLS Why TIS

Therapies In Schools Project BRINGING THERAPIES INTO THE HEART OF SCHOOLS Why TIS Losing Tribunals due to lack of theraptic input. Non maintained schools were able to sell packages as all therapists in house. We need The

239 views • 13 slides
Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC

Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC

Progress in MS: Current and Emerging Therapies Presented by: Dr. Kathryn Giles, MD MSc FRCPC Cambridge, Ontario, Canada Todays Discussion Natural History and Classification of MS Treating MS Management of the Disease Community

1.06k views • 38 slides
Experience from shadowing different therapies for patients with Multiple Sclerosis in UK and

Experience from shadowing different therapies for patients with Multiple Sclerosis in UK and

Experience from shadowing different therapies for patients with Multiple Sclerosis in UK and Poland Malgorzata Mauriange Physiotherapist Benenden Hospital Therapies applied in Poland Therapies Programmes are developed and based on the

404 views • 23 slides
How we have developed our home therapies programme Sr Elaine Gibson Shrewsbury and Telford NHS

How we have developed our home therapies programme Sr Elaine Gibson Shrewsbury and Telford NHS

How we have developed our home therapies programme Sr Elaine Gibson Shrewsbury and Telford NHS Hospitals Trust (SaTH) Growth of Home therapies Clinical lead for home therapies from 2015 Merging of PD and HHD nursing teams to create

454 views • 9 slides
Unproven cell-based therapies: a risk to public health and to the development of advanced

Unproven cell-based therapies: a risk to public health and to the development of advanced

Unproven cell-based therapies: a risk to public health and to the development of advanced therapies Dr Kieran Breen Committee for Advanced Therapies An agency of the European Union Cell-based therapies Cell- based medicinal products have the

378 views • 11 slides
From Big Data to Therapies: Roadmap Studies in Alzheimers and Related Disorders Please join us

From Big Data to Therapies: Roadmap Studies in Alzheimers and Related Disorders Please join us

From Big Data to Therapies: Roadmap Studies in Alzheimers and Related Disorders Please join us on September 12th from 11am-noon in B02 CSL Alzheimers disease (AD) and related neurodegenerative disorders represent the 21 st century epidemic

465 views • 3 slides

More recommend